Therefore, a potential strategy for future tests in MCL could be to incorporate novel providers2526during induction or early post-remission chemotherapy. disease analysis. Using peripheral blood monitoring, 18 of 39 (46%) accomplished molecular remission following induction therapy. The molecular remission rate improved from 46 to 74% after one course of intensification therapy. Twelve of 21 minimal residual disease positive individuals (57%) progressed within three years of follow up compared to 4 of 18 (22%) molecular remission individuals (P=0.049). Detection of minimal residual disease following induction therapy expected disease progression having a risk percentage of 3.7 (P=0.016). The 3-yr probability of time to progression among those who were in molecular remission after induction chemotherapy was 82% compared to 48% in individuals with detectable minimal residual disease. The NU 9056 prediction of time to progression by post-induction minimal residual disease was self-employed of additional prognostic factors in multivariable analysis. == Conclusions == Detection of minimal residual disease following induction immunochemotherapy was an independent predictor of time to progression following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma.The clinical trial was registered atClinicalTrials.gov:NCT00020943. Keywords:minimal residual disease, progression-free survival, MCL, induction, chemotherapy == Intro == Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkins lymphoma (NHL) having a median overall survival (OS) of approximately 4.8 years following standard combination chemotherapy.1Current treatment strategies include the addition of rituximab to different combination chemotherapy regimens including CHOP and Hyper-CVAD.23Several phase II studies and one phase III study proven that remission induction with combination chemotherapy followed by NU 9056 dose intensification with autologous stem cell transplantation (ASCT) prolongs progression-free survival (PFS) for patients with previously untreated MCL.46 The prognostic role of minimal residual disease (MRD) has been established in MCL.7The introduction of rituximab to high-dose Ara-C led to successfulin vivopurging of MCL cells from peripheral blood cells containing CD34 harvested from patients with MCL, resulting in a high molecular remission (MRD-) rate of over 90% and improved clinical outcome.89Recently, MRD was evaluated retrospectively by quantitative real-time polymerase chain reaction (RQ-PCR) of clonal IgH rearrangements NU 9056 in 29 patients with MCL treated with high-dose radio-chemotherapy and ASCT. Molecular remission after ASCT strongly expected for improved end result.7Andersenet al.showed that molecular relapse may occur many years after ASCT in NU 9056 MCL, and NU 9056 pre-emptive treatment using rituximab for MRD recognized by RQ-PCR was able to re-induce molecular remission, and hold off or prevent clinical relapse.10 CALGB 59909 was a recently published prospective trial that shown the efficacy and tolerability of aggressive induction immunochemotherapy followed by ASCT for individuals up to 70 years of age with previously untreated MCL.11In the present study, the prognostic impact of MRD during treatment on time to progression (TTP) and overall survival (OS) was analyzed prospectively in patients with MCL treated within the CALGB 59909 clinical trial. Our study demonstrates for the first time that MRD status after induction immunochemotherapy expected TTP individually of additional previously defined prognostic factors. == Design and Methods == == Individuals characteristics and sample collection for minimal residual disease == Seventy-eight individuals began treatment according to the CALGB 59909 medical protocol.11The study was approved by the Institutional Review Board of the participating institutions. All the participants authorized an institutional evaluate board-approved educated consent document. The study was carried out in accordance with the Declaration of Helsinki and was authorized onclinicaltrials.gov(NCT00020943). Briefly, individuals received two cycles of induction chemotherapy using rituximab, high-dose methotrexate and augmented-dose CHOP chemotherapy, which was followed by high-dose consolidation and stem cell mobilization using high-dose cytarabine, etoposide, and rituximab given as an in vivopurge. Individuals consequently underwent ASCT using a cyclophosphamide, BCNU, and etoposide (CBV) preparative routine. Two weekly doses of maintenance rituximab were administered following recovery from ASCT (Number 1). Sixty-seven individuals (86%) received the protocol transplant. == Number 1. == CALGB 59909 treatment schema and sample collection. In 11 individuals, no clone specific molecular marker was recognized; therefore, 84% of the individuals had successful recognition of an allele specific primer-probe arranged for MRD detection. Seventeen individuals had inadequate sample collection at sequential time points (n=15) or were not transplanted (n=2) within the protocol. Thus, a total of 39 individuals had sequential samples and were evaluated for KSHV ORF62 antibody MRD during treatment on CALGB 59909. MRD status was determined by RQ-PCR using combined peripheral blood (PB) and bone marrow (BM) biopsy samples post induction treatment from your peripheral blood stem cell apheresis collection, and in PB and BM samples three months post ASCT (samples from PB or BM at each time point are outlined inFigure 1). All the individuals gave their authorized informed consent.